Ignyta Inc (NASDAQ:RXDX) released its earnings data. The company reported ($0.28) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.37) by $0.09. Finally, analysts at Ladenburg Thalmann initiated coverage on shares of company in a research note on Monday, March 24th. They set a “buy” rating and a $20.00 price target on the stock. Ignyta Inc (NASDAQ:RXDX) stock performance was 13.12% in last session and finished the day at $7.24. Traded volume was 54,641.00million shares in the last session and the average volume of the stock remained 101.16K shares.

Onconova Therapeutics Inc (NASDAQ:ONTX) posted its quarterly earnings results on 12 May 2014. The company reported ($0.87) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.78) by $0.09, Stock Ratings Network.com reports. Finally, analysts at Piper Jaffray downgraded shares of the company from an “overweight” rating to a “neutral” rating in a research note on Thursday, February 20th. They now have a $9.00 price target on the stock, down previously from $38.00. Onconova Therapeutics Inc (NASDAQ:ONTX) rose 5.57 percent to $5.12 Thursday on volume of 108,220.00million shares. The intra-day range of the stock was $4.85 to $5.12. has a market capitalization of $110.80million.

Cempra Inc (NASDAQ:CEMP) Director John Johnson acquired 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 23rd. The stock was purchased at an average price of $9.10 per share, with a total value of $91,000.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $91,000. Cempra Inc (NASDAQ:CEMP)’s stock on May 29, 2014 reported a increase of 5.81% to the closing price of $9.66. Its fifty two weeks range is $6.95 -$15.38. The total market capitalization recorded $320.73million. The overall volume in the last trading session was 247,327.00million shares. In its share capital, CEMP has 33.20million outstanding shares.

A better-ranked stock in the pharma sector is ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), carrying a Zacks Rank #1 (Strong Buy). On Thursday, shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) advanced 5.99% to close the day at $32.76. Company return on investment (ROI) is 2.20% and its monthly performance is recorded as 4.93%. ANI Pharmaceuticals Inc (NASDAQ:ANIP) quarterly revenue growth is 0.09%.